1Y Target$21.20Near-term target
5Y Target$44.03Compound horizon
10Y Target$114.57Long-dated conviction
FCF$2.8bTTM · 03/26BFCF $2.8b — solid, comfortably covers operations and capital return · TTM computed from 4 most-recent quarters (TTM · 03/26).
Rev+52.6%TTM YoYARevenue +52.6% — hypergrowth, top decile
D/E0.29A-D/E 0.29 — conservative leverage, strong balance sheet
P/S0.5xAP/S 0.5x — deep value on sales
PEG——PEG not meaningful — earnings growth negative or data unavailable
Why now
Healthcare Plans · market cap $6.6b. 14% off the 52-week high of $25.58. Revenue growing +53% — in hypergrowth territory. 10 sell-side analysts rate this a Hold with a mean 1-yr target of $21.20 (implying -3% upside).
Moat
Speculative bucket — the moat thesis is forward-looking; without proven margin structure or capital efficiency yet, the durability argument is about IP / network effects / first-mover position that the company hasn't fully monetized.
Risk
Currently unprofitable (margin -0.3%) — path to GAAP profitability is the core thesis risk. Beta 2.34 implies above-market volatility — position-size to the drawdowns this name will produce in a market correction, not to its bull-case return. ROE -3% is below the long-run sustainable threshold of ~10% — capital efficiency would need to improve for the equity base to compound at the market rate.
Horizon
1-3 yr $21.20 (10-analyst consensus) — catalyst-driven; binary events dominate. 5 yr $44.03 — requires the platform / technology to reach commercial scale. 10 yr $114.57 — return distribution heavily skewed.
Not investment advice. The Bull Rankings publishes a quantitative ranking model and accompanying analysis for general informational purposes only. Nothing on this page is a recommendation to buy, sell, or hold any security; nothing is personalized to your circumstances, risk tolerance, or tax situation. Investing carries the risk of loss — invest at your own risk and consider consulting a licensed financial professional before acting on anything you read here. See
terms and
methodology for full disclosures.